Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argent BiopharmaRGTLF Equity-to-Asset is -4.20 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Argent Biopharma ranks worse than 97.72% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Argent Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-5.61 Mil. Argent Biopharma's Total Assets for the quarter that ended in Dec. 2025 was $1.34 Mil.
Therefore, Argent Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -4.20.
The historical rank and industry rank for Argent Biopharma's Equity-to-Asset or its related term are showing as below:
RGTLF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.2 Med: 0.42 Max: 0.93
Current: -4.2
During the past 13 years, the highest Equity to Asset Ratio of Argent Biopharma was 0.93. The lowest was -4.20. And the median was 0.42.
RGTLF's Equity-to-Asset is ranked worse than 97.72% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs RGTLF: -4.20
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Argent Biopharma Equity-to-Asset Related Terms
Argent Biopharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Argent Biopharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (RGTLF) has a Equity-to-Asset of -4.20 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #984 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 97.7%.
Is Argent Biopharma's Equity-to-Asset too high?
Argent Biopharma's current Equity-to-Asset is -4.20. Based on the distribution chart, Argent Biopharma ranks #984 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #984 out of 1007 companies for Equity-to-Asset. This places Argent Biopharma in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Equity-to-Asset is -4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Equity-to-Asset is -4.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Equity-to-Asset is -4.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 
